



September 5, 2017

## **Eleven Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference**

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, will present a company overview at the Rodman & Renshaw 19<sup>th</sup> Annual Global Investment Conference in New York on Monday, September 11, 2017 at 3:00 p.m. EDT.

A live webcast can be accessed from the Investors & Media section of Eleven's website, [www.elevenbio.com](http://www.elevenbio.com). An archived replay of the webcast will be available on the Company's website for 90 days after the conference.

### **About Eleven Biotherapeutics**

Eleven Biotherapeutics, Inc. is a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based upon the Company's targeted protein therapeutics (TPTs) platform. The Company's TPTs incorporate a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule in order to achieve focused tumor cell killing. The Company believes its TPT approach offers significant advantages in treating cancer over existing antibody drug conjugate technologies. The Company believes its TPTs provide effective tumor targeting with broader cancer cell-killing properties than are achievable with small molecule payloads that require tumor cell proliferation and face multi-drug resistance mechanisms. Additionally, the Company believes that its TPT's cancer cell-killing properties promote an anti-tumor immune response that will potentially combine well with immune oncology drugs such as checkpoint inhibitors. For more information please refer to the Company's website at [www.elevenbio.com](http://www.elevenbio.com).

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170905005550/en/>

Stern Investor Relations, Inc.  
Hannah Deresiewicz, 212-362-1200  
[hannahd@sternir.com](mailto:hannahd@sternir.com)

Source: Eleven Biotherapeutics, Inc.

News Provided by Acquire Media